Many CDMOs have taken actions to meet the growing demand of viral vector development and manufacturing services for clinical trials, as well as for commercial scale production. While capacity is important, there are only a few companies who provide services across the entire supply and value chain. So, what should you expect when choosing a true one-stop-shop as a CDMO partner in the gene therapy space?
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures, their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps. 90% of the disposal costs are saved as well as more than 40% of the pipet tip consumption costs. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
For its first phocean edition, BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. Over 1,150 attendees from over 35 countries attended BioFIT’s 8th edition: 120+ exhibitors, 70 speakers, 16 conferences and 4 projects elected as the most innovative in their categories were gathered in Marseille at Parc Chanot on December 10th and 11th.
The 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.
At the CPhI Worldwide in Frankfurt, the winners of the 2019 Pharma awards were announced. The CEO of WuXi AppTec, Dr. Ge Li, received the award in category CEO of the year among 12 other categories.
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps.
Many users in research labs like to store their assay components such as assay antibodies, conjugates, antigens, calibrators or coated ELISA plates for a while without losing functionality.
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated efficient lysis reagents for e.g. different plant tissues. In contrast to common bind-wash-elute procedures, the process does not require washing steps. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.
Manufacturers respond to stricter regulations with novel approaches.
Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.